178 related articles for article (PubMed ID: 11753268)
1. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants.
de Wildt SN; Kearns GL; Hop WC; Murry DJ; Abdel-Rahman SM; van den Anker JN
Clin Pharmacol Ther; 2001 Dec; 70(6):525-31. PubMed ID: 11753268
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of oral midazolam in preterm infants.
de Wildt SN; Kearns GL; Hop WC; Murry DJ; Abdel-Rahman SM; van den Anker JN
Br J Clin Pharmacol; 2002 Apr; 53(4):390-2. PubMed ID: 11966671
[TBL] [Abstract][Full Text] [Related]
3. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.
Kearns GL; Robinson PK; Wilson JT; Wilson-Costello D; Knight GR; Ward RM; van den Anker JN;
Clin Pharmacol Ther; 2003 Oct; 74(4):312-25. PubMed ID: 14534518
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
5. Ontogeny of midazolam glucuronidation in preterm infants.
de Wildt SN; Kearns GL; Murry DJ; Koren G; van den Anker JN
Eur J Clin Pharmacol; 2010 Feb; 66(2):165-70. PubMed ID: 19838691
[TBL] [Abstract][Full Text] [Related]
6. Dose-linearity of the pharmacokinetics of an intravenous [
van Groen BD; Vaes WH; Park BK; Krekels EHJ; van Duijn E; Kõrgvee LT; Maruszak W; Grynkiewicz G; Garner RC; Knibbe CAJ; Tibboel D; de Wildt SN; Turner MA
Br J Clin Pharmacol; 2019 Oct; 85(10):2332-2340. PubMed ID: 31269280
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oral and intravenous indomethacin in preterm infants.
Bhat R; Vidyasagar D; Fisher E; Hastreiter A; Ramirez JL; Burns L; Evans M
Dev Pharmacol Ther; 1980; 1(2-3):101-10. PubMed ID: 6927543
[TBL] [Abstract][Full Text] [Related]
8. Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome.
Al Za'abi M; Donovan T; Tudehope D; Woodgate P; Collie LA; Charles B
Ther Drug Monit; 2007 Dec; 29(6):807-14. PubMed ID: 18043480
[TBL] [Abstract][Full Text] [Related]
9. Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study.
Smyth JM; Collier PS; Darwish M; Millership JS; Halliday HL; Petersen S; McElnay JC
Br J Clin Pharmacol; 2004 Sep; 58(3):249-58. PubMed ID: 15327584
[TBL] [Abstract][Full Text] [Related]
10. Indomethacin impairs coronary perfusion in infants with hemodynamically significant ductus arteriosus.
Sehgal A; Ramsden CA; McNamara PJ
Neonatology; 2012; 101(1):20-7. PubMed ID: 21791936
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and disposition of indomethacin in preterm infants.
Friedman CA; Temple DM; Wender DF; Parks BR; Rawson JE
Dev Pharmacol Ther; 1991; 17(1-2):1-7. PubMed ID: 1811914
[TBL] [Abstract][Full Text] [Related]
12. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus.
Van Overmeire B; Touw D; Schepens PJ; Kearns GL; van den Anker JN
Clin Pharmacol Ther; 2001 Oct; 70(4):336-43. PubMed ID: 11673749
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics.
Lee TC; Charles BG; Harte GJ; Gray PH; Steer PA; Flenady VJ
Anesthesiology; 1999 Feb; 90(2):451-7. PubMed ID: 9952152
[TBL] [Abstract][Full Text] [Related]
14. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Phimmasone S; Kharasch ED
Clin Pharmacol Ther; 2001 Dec; 70(6):505-17. PubMed ID: 11753266
[TBL] [Abstract][Full Text] [Related]
15. A preliminary study on pharmacokinetics of oral indomethacin in premature infants in north India.
Sharma PK; Garg SK; Narang A
Indian J Med Res; 2003 Apr; 117():164-9. PubMed ID: 14604305
[TBL] [Abstract][Full Text] [Related]
16. Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model.
Völler S; Flint RB; Beggah F; Reiss I; Andriessen P; Zimmermann LJI; van den Anker JN; Liem KD; Koch BCP; de Wildt S; Knibbe CAJ; Simons SHP
J Clin Pharmacol; 2019 Oct; 59(10):1300-1308. PubMed ID: 31093992
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
de Wildt SN; de Hoog M; Vinks AA; van der Giesen E; van den Anker JN
Crit Care Med; 2003 Jul; 31(7):1952-8. PubMed ID: 12847388
[TBL] [Abstract][Full Text] [Related]
18. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age.
van den Anker JN; Schoemaker RC; Hop WC; van der Heijden BJ; Weber A; Sauer PJ; Neijens HJ; de Groot R
Clin Pharmacol Ther; 1995 Dec; 58(6):650-9. PubMed ID: 8529330
[TBL] [Abstract][Full Text] [Related]
19. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
20. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
